All In Biotech

Drug Trial Radar · NCT07905183

A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs

A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Dec 31, 2026

Primary completion

Dec 31, 2028

Study completion Jul 2033

Sponsor

Lead sponsor
Enliven TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.

Conditions

  • Chronic Myeloid Leukemia (CML)
  • Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
  • Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML

Interventions

  • ELVN-001Drug

    ELVN-001 orally daily

  • TKIDrug

    TKI orally daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKITime frame: 24 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Investigative Clinical Research of Indiana, LLC

    Indianapolis, Indiana · Recruiting

  • Atlantic Health System

    Morristown, New Jersey · Recruiting

  • Community Center Trials of Utah

    Ogden, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.